Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Verastem, Inc. (VSTM : NSDQ)
 
 • Company Description   
Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.

Number of Employees: 78

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.80 Daily Weekly Monthly
20 Day Moving Average: 2,403,050 shares
Shares Outstanding: 54.95 (millions)
Market Capitalization: $263.76 (millions)
Beta: 0.71
52 Week High: $9.10
52 Week Low: $2.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -22.33% -26.54%
12 Week 6.19% -10.91%
Year To Date -7.16% -13.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
117 KENDRICK STREET SUITE 500
-
NEEDHAM,MA 02494
USA		 ph: 781-292-4200
fax: -		 dcalkins@verastem.com http://www.verastem.com
 
 • General Corporate Information   
Officers
Daniel W. Paterson - President and Chief Executive Officer
Matthew E. Ros - Chief Operating Officer
Daniel Calkins - Chief Financial Officer
Paul Bunn - Director
Robert Gagnon - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92337C203
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 54.95
Most Recent Split Date: 6.00 (0.08:1)
Beta: 0.71
Market Capitalization: $263.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.72 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 23.81%
vs. Previous Quarter: 27.82%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -2,003.62
ROA
06/30/25 - -
03/31/25 - -127.97
12/31/24 - -114.29
Current Ratio
06/30/25 - -
03/31/25 - 3.50
12/31/24 - 3.07
Quick Ratio
06/30/25 - -
03/31/25 - 3.50
12/31/24 - 3.07
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1,486.92
12/31/24 - -1,304.52
Book Value
06/30/25 - -
03/31/25 - -0.63
12/31/24 - -0.65
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©